Premium
[P3–410]: ASSOCIATION OF PAST AND CURRENT BODY MASS INDEX WITH BRAIN AMYLOID DEPOSITION AND NEURODEGENERATION IN COGNITIVELY NORMAL ELDERLY
Author(s) -
Lee Seung Hoon,
Byun Min Soo,
Lee Jun Ho,
Yi Dahyun,
Sohn Bo Kyung,
Lee JunYoung,
Choe Young Min,
Choi Hyo Jung,
Baek Hyewon,
Kim Hyun Jung,
Han Myeongil,
Lee Dong Young
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1627
Subject(s) - body mass index , dementia , population , psychology , medicine , alzheimer's disease , entorhinal cortex , positron emission tomography , disease , hippocampus , neuroscience , environmental health
scan. All MRIs were analyzed for cortical microinfarcts (CMI) as well as acutemicroinfarcts (AMI). CMIwere rated according to a new scale for 3.0Tderived from7.0TMRI andhistopathological analysis.Microinfarcts were defined as hypointense on T1-MPRAGE, perpendicular to the cortex and under 5mm in size, and hyperintense or isointense on FLAIR. AMI were rated and defined as small hyperintense dots on DWI. Associations between CMI and AMI and imaging markers and clinical parameters were determined with generalized linear models. Results: The prevalence of CMI was 43%, and AMI 5% in thewhole cohort.Ahighnumber ofCMI, but notAMI,were associated with high age (B1⁄40.2, P1⁄40.02), and lower cognitive score (B1⁄4-0.05, P1⁄40.002). Similarly, a high number of CMI, but not AMI, showed associations with lower amyloid levels in the cerebrospinal fluid (B1⁄4-0.02, P1⁄40.001). No associations were seen with other imaging markers and clinical parameters for both CMI and AMI. Conclusions: CMI are likely a more important marker in cognitive impairment than AMI. AMI is a rare and temporary manifestation, that may turn into a CMI once the acute phase is over. The association of CMI with low amyloid cerebrospinal fluid, ie high amyloid brain deposition, suggests that CMImay be amarker of either Alzheimer’s pathology, or cerebral amyloid angiopathy. Future studies need to focus on assessment of different amyloid peptides to better differentiate the association of CMI with cerebral amyloid angiopathy and Alzheimer’s disease.